Weight loss outcomes with trulicity
Pro Research Analysisby 
Searched over 200M research papers
Trulicity (Dulaglutide) and Weight Loss Outcomes
Weight Loss Efficacy in Obesity and Type 2 Diabetes
Trulicity (dulaglutide), a GLP-1 receptor agonist, has shown promising results for weight loss in both clinical and real-world settings. In a case involving a patient with morbid obesity, dulaglutide led to a significant decrease in body weight after other weight reduction methods had failed, suggesting its potential as an effective pharmacotherapy for obesity management when lifestyle changes alone are insufficient . Similarly, in patients with type 2 diabetes and obesity, dulaglutide administration resulted in measurable reductions in body mass index (BMI) over 3 to 9 months, alongside improved blood glucose control . These findings indicate that dulaglutide can support weight loss in diverse patient populations, including those with complex health needs 13.
Real-World Weight Loss Outcomes with GLP-1s Including Trulicity
A large real-world analysis of over 12,000 patients treated with GLP-1 medications, including dulaglutide, found an average weight loss of 16.2% at 12 months and 17.2% at 24 months when combined with an intensive lifestyle intervention . Even among patients who experienced medication access disruptions, clinically significant weight loss was maintained, though slightly less than those with uninterrupted treatment . This demonstrates that dulaglutide, as part of a comprehensive obesity management program, can lead to substantial and sustained weight loss in real-world practice.
Dulaglutide for Prevention of Weight Gain
Dulaglutide is also being studied for its potential to prevent weight gain in patients at risk, such as those taking antipsychotic medications known to cause weight gain. A randomized controlled trial is underway to assess whether dulaglutide can prevent antipsychotic-induced weight gain, with the primary outcome being mean weight change after 24 weeks . This highlights dulaglutide’s potential not only for weight loss but also for weight gain prevention in specific populations.
Additional Benefits and Considerations
Beyond weight loss, dulaglutide offers other health benefits, such as improved glycemic control and reduced cardiovascular risk, making it a valuable option for patients with type 2 diabetes and obesity . Its once-weekly dosing and generally good tolerability further support its use in long-term management .
Conclusion
Dulaglutide (Trulicity) is effective for weight loss in patients with obesity and type 2 diabetes, both in clinical trials and real-world settings. It can also help prevent weight gain in high-risk groups and offers additional metabolic and cardiovascular benefits. These outcomes make dulaglutide a strong option for patients struggling with weight management, especially when combined with lifestyle interventions 1345.
Sources and full results
Most relevant research papers on this topic